secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2026-08-26T20:30:04+00:00
Accession:  0001104659-26-101531
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Animal Health reports record FY2026 results, raises FY2027 guidance
--------------------------------------------------------------------------

- Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).
- FY2026 net sales $1,518.1M (+17%); net income $99.7M; adjusted EBITDA $255.0M (+39%).
- FY2027 guidance: net sales $1.55-1.60B, adjusted EBITDA $258-268M, adjusted net income $140-147M.
- Plans to close Chicago Heights manufacturing facility; production ceases summer 2027, ~100 employees affected.
- Regulatory uncertainty on virginiamycin in Brazil; guidance assumes minimal sales, potential upside if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/0001104659-26-101531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/pahc-20260826x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-101531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer